Boothbay Fund Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Boothbay Fund Management’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-43,670	Closed	-$2.97M	–	2810
2022 Q3	$2.97M	Buy	+43,670	New	+$2.41M	0.07%	393
2022 Q1	–	Sell	-18,695	Closed	-$547K	–	2675
2021 Q4	$547K	Buy	+18,695	New	+$579K	0.01%	975
2019 Q2	–	Sell	-8,773	Closed	-$504K	–	950
2019 Q1	$464K	Sell	8,773 -9,280	-51%	-$456K	0.05%	403
2018 Q4	$741K	Buy	+18,053	New	+$676K	0.11%	196

Other funds holding GBT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Boothbay Fund Management's GBT Position: Q4 2022 in Review

Boothbay Fund Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 43,670 shares — an estimated $2.97M sold.

Boothbay Fund Management first reported a position in GBT in Q4 2018 and held it in 4 quarters. The position peaked at $2.97M in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

Boothbay Fund Management reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
Boothbay Fund Management sold 43,670 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $2.97M.
Boothbay Fund Management first reported a position in Global Blood Therapeutics, Inc. in Q4 2018 and held it in 4 quarters.
Boothbay Fund Management's Global Blood Therapeutics, Inc. position peaked at $2.97M in Q3 2022.
2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Boothbay Fund Management's 13F filing for Q4 2022, filed 14 Feb 2023.